Home > Haematology > EHA 2021 > Thrombotic and Thrombocytopenic Disorders including COVID-19 related > Fostamatinib effectively increased platelet counts in immune thrombocytopenic purpura

Fostamatinib effectively increased platelet counts in immune thrombocytopenic purpura

Presented By
Prof. Waleed Ghanima, University of Oslo, Norway
Conference
EHA 2021
Trial
Phase 3, FIT-1,-2,-3
Fostamatinib effectively elevated platelet counts and provided durable response in patients with immune thrombocytopenic purpura (ITP), as shown in phase 3 clinical trials. Thus, fostamatinib can be considered a valuable new treatment approach for ITP. Prof. Waleed Ghanima (University of Oslo, Norway) presented results of a phase 3 programme that assessed the efficacy, safety, and durability of response of fostamatinib in patients with ITP [1]. In 2 parallel, double-blind, placebo-controlled phase 3 studies (FIT-1 NCT02076412; FIT-2 NCT02076399), 150 patients were randomised 2:1 to receive either 100 mg fostamatinib twice daily (...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on